Suppression of plasma androgen levels with a combination therapy of depot-estrogen (Turisteron) and Dexamethasone in patients with prostatic cancer

Exp Clin Endocrinol. 1989;94(3):239-43. doi: 10.1055/s-0029-1210905.

Abstract

Treatment of patients with prostatic cancer with a combination of 1-2 mg depot-estrogen (ethinylestradiol sulfonate = Turisteron) per week and 1 mg dexamethasone per day suppressed the mean testosterone (T) level to 2.8% (0.53 nmol/l), the free T to 0.8% (1.9 pmol/l) and the adrenal androgens (AA) -- androstenedione (A), dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) -- to more than 40% of the initial values. Treatment with Turisteron alone (2 mg per week) did not change the DHEA and DHEAS levels but decreased plasma A concentration to 65% (2.96 nmol/l) of the initial values.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgens / blood*
  • Dexamethasone / pharmacology*
  • Drug Therapy, Combination
  • Ethinyl Estradiol / analogs & derivatives*
  • Ethinyl Estradiol / pharmacology
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms / blood*
  • Prostatic Neoplasms / drug therapy

Substances

  • Androgens
  • ethinyl estradiol sulfonate
  • Ethinyl Estradiol
  • Dexamethasone